Page last updated: 2024-11-02

oxybutynin and Obesity

oxybutynin has been researched along with Obesity in 11 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Treatment-emergent adverse events of 2% or greater in the LNG/EE contraceptive patch were nasopharyngitis (5."2.80Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. ( Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015)
" However, the conventional approaches to apply browning agents systematically suffer from off-target effects, multiple dosage requirements, and poor patient compliance."2.72Strategies for Browning Agent Delivery. ( Gu, Z; Sheng, T; Zhang, W; Zhang, Y, 2021)
"Current treatments toward obesity including diet, physical exercise, pharmacological therapy, as well as surgeries are always associated with low effectiveness or undesired systematical side effects."1.46Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment. ( Gu, Z; Liu, Q; Qiang, L; Wang, J; Yu, J; Yu, S; Zhang, Y, 2017)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (90.91)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Lua, LL1
Pathak, P1
Dandolu, V1
Zhang, W1
Sheng, T1
Gu, Z2
Zhang, Y2
Dangol, M1
Kim, S1
Li, CG1
Fakhraei Lahiji, S1
Jang, M1
Ma, Y1
Huh, I1
Jung, H1
Liu, Q1
Yu, J1
Yu, S1
Wang, J1
Qiang, L1
Ariamoghaddam, AR1
Ebrahimi-Hosseinzadeh, B1
Hatamian-Zarmi, A1
Sahraeian, R1
Kaunitz, AM2
Portman, D1
Westhoff, CL2
Archer, DF2
Mishell, DR2
Rubin, A1
Foegh, M2
Reinecke, I1
Bangerter, K1
Merz, M1
Hurley, C1
Semancik, L1
Simmons, KB1
Edelman, AB1
Lycett, D1
Munafò, M1
Johnstone, E1
Murphy, M1
Aveyard, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.[NCT01181479]Phase 31,504 participants (Actual)Interventional2010-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cycle Control

Measuring the breakthrough bleeding (BTB) and/or breakthrough spotting (BTS). Measured as a percent of total number of cycles in each Arm/Group with BTB and/or BTS. (NCT01181479)
Timeframe: 6 months

Interventionpercentage of cycles with BTB/BTS (Number)
AG200-15 for Cycle 1-623.9
Lessina21.2

Patch Adhesion by Investigator Evaluation at Each Visit

"Evaluation of patch adhesion was determined using the following scores:~0: >= 90% adhered (no lift)~>= 75% adhered but < 90% (some edges showing lift)~>= 50% adhered but < 75% (half of system lifts off)~< 50% (> half of system lifts off, but undetached)~patch completely detached" (NCT01181479)
Timeframe: 1 year

InterventionScore on a scale (Mean)
All Subjects Who Applied AG200-150.29

Pregnancy

Pregnancy outcomes was determine by measuring Pearl index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use. (NCT01181479)
Timeframe: AG200-15: 6 months; Lessina: 6 months; AG200-15: 1 year

InterventionPearl Index (Number)
AG200-15 for Cycle 7-135.41
Lessina6.67
AG200-15 for Cycle 1-136.43

Self-reported Irritation at Application Site

"Evaluation of irritation at application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year

InterventionScore on scale (Mean)
All Subjects Who Applied AG200-151.35

Self-reported Itching at Patch Application Site

"Evaluation of itching at patch application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year

InterventionScore on a scale (Mean)
All Subjects Who Applied AG200-151.48

Pharmacokinetics of Levonorgestrel (LNG) and Ethinyl Estradiol (EE)

Measurement of plasma concentrations of LNG and EE for cycles 2, 6 and 13. (NCT01181479)
Timeframe: Lessina: 6 months; AG200-15: 1 year; AG200-15: 6 months

,,
Interventionpg/ml (Mean)
EE for cycle 2EE cycle 6EE cycle 13LNG cycle 2LNG cycle 6LNG cycle 13
AG200-15 for Cycle 1-1330.536.731120117531590
AG200-15 for Cycles 7-13NANA33.4NANA1750
Lessina Cycles 1-635.440.1NA23862611NA

Reviews

2 reviews available for oxybutynin and Obesity

ArticleYear
Strategies for Browning Agent Delivery.
    Pharmaceutical research, 2021, Volume: 38, Issue:8

    Topics: Adipocytes, Brown; Adipocytes, White; Animals; Anti-Obesity Agents; Drug Delivery Systems; Humans; M

2021
Hormonal contraception and obesity.
    Fertility and sterility, 2016, Volume: 106, Issue:6

    Topics: Administration, Cutaneous; Administration, Oral; Body Mass Index; Contraception; Contraception, Post

2016

Trials

3 trials available for oxybutynin and Obesity

ArticleYear
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
    Obstetrics and gynecology, 2014, Volume: 123, Issue:2 Pt 1

    Topics: Adolescent; Adult; Body Mass Index; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Dr

2014
Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Contraception, 2014, Volume: 90, Issue:3

    Topics: Adolescent; Adult; Body Mass Index; Contraceptive Agents, Female; Drug Combinations; Estradiol; Ethi

2014
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
    American journal of obstetrics and gynecology, 2015, Volume: 212, Issue:3

    Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Combinations

2015

Other Studies

6 other studies available for oxybutynin and Obesity

ArticleYear
Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Neurourology and urodynamics, 2017, Volume: 36, Issue:8

    Topics: Adolescent; Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Medication Adheren

2017
Anti-obesity effect of a novel caffeine-loaded dissolving microneedle patch in high-fat diet-induced obese C57BL/6J mice.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, Nov-10, Volume: 265

    Topics: Administration, Cutaneous; Animals; Anti-Obesity Agents; Caffeine; Cell Survival; Cholesterol; Diet,

2017
Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment.
    ACS nano, 2017, 09-26, Volume: 11, Issue:9

    Topics: Adipocytes, White; Adipose Tissue, White; Animals; Anti-Obesity Agents; Drug Delivery Systems; Hypog

2017
In vivo anti-obesity efficacy of curcumin loaded nanofibers transdermal patches in high-fat diet induced obese rats.
    Materials science & engineering. C, Materials for biological applications, 2018, Nov-01, Volume: 92

    Topics: Adipose Tissue; Administration, Cutaneous; Animals; Cholesterol; Curcumin; Diet, High-Fat; Drug Libe

2018
Transdermal Patches: Considerations in Special Populations.
    Connecticut medicine, 2016, Volume: 80, Issue:1

    Topics: Administration, Cutaneous; Age Factors; Cachexia; Humans; Obesity; Pharmaceutical Preparations; Tran

2016
Associations between weight change over 8 years and baseline body mass index in a cohort of continuing and quitting smokers.
    Addiction (Abingdon, England), 2011, Volume: 106, Issue:1

    Topics: Adult; Aged; Body Mass Index; England; Family Practice; Female; Humans; Male; Middle Aged; Nicotine;

2011